Morgan Stanley analyst Michael Ulz has reiterated their bullish stance on GUTS stock, giving a Buy rating on September 26.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ulz has given his Buy rating due to a combination of factors that highlight the promising potential of Fractyl Health, Inc.’s Revita therapy. The recent data from the REMAIN-1 midpoint cohort indicates that patients treated with Revita maintained weight loss even after discontinuing GLP-1 drugs, which is a significant achievement compared to the weight regain observed in sham-treated patients. This outcome not only surpasses expectations but also suggests a meaningful benefit for patients, physicians, and payers, especially considering the typical weight regain associated with GLP-1 withdrawal.
Furthermore, the safety profile of Revita remains consistent with previous studies, with no serious adverse events related to the treatment. The positive results from the three-month data boost confidence as the company moves towards pivotal studies, with early feedback from payers indicating a favorable reception for Revita as a durable solution. These factors, along with the expectation of further data updates and the financial stability to support operations into early 2027, underpin Michael Ulz’s optimistic outlook and Buy rating for Fractyl Health, Inc.
In another report released on September 26, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.
GUTS’s price has also changed slightly for the past six months – from $1.270 to $1.340, which is a 5.51% increase.